PolyActiva

Chronic ocular diseases require lifelong therapeutics, but current treatments face challenges like reduced efficacy and poor patient compliance.

PolyActiva’s PREZIA technology enables biodegradable ocular implants for treating various eye diseases, currently in clinical development.

PREZIA technology provides precise, controlled drug delivery for ocular implants, based on research in pharmaceutical and polymer chemistry.

Publications Sulistio A, Mansfeld F, Reyes-Ortega F, et al. Intra-articular Treatment of Osteoarthritis with Diclofenac-Conjugated Polymer Reduces Inflammation and Pain. CS Appl. Bio Mater (2019), 2, 2822−2832. doi: 10.1021/acsabm.9b00232. Sulistio A, Reyes-Ortega F, D’Souza AM, et al. Precise control of drug loading and release of an NSAID-polymer conjugate for long term osteoarthritis intra-articular drug delivery. […]

PolyActiva and RareSight Inc. collaborate to develop first-in-class therapies for rare pediatric retinal diseases with no approved treatments.

PolyActiva commences its first Phase I clinical trial.

PolyActiva completes recruitment in key Phase I glaucoma implant safety study. Six-month treatment period demonstrated.

PolyActiva raises AUD$9.2M in Series B venture funding.

PolyActiva focuses on biodegradable implants for sustained drug delivery in ophthalmic diseases like glaucoma.

Jerry St. Peter serves as PolyActiva’s Chief Executive Officer and Director, bringing over 30 years of biopharma leadership in strategy, R&D, and commercial operations.

PolyActiva develops biodegradable ocular implants for site-specific, controlled drug delivery to treat ophthalmic diseases.

PolyActiva’s PREZIA platform delivers sustained drug release for ophthalmic diseases, improving patient outcomes and quality of life.

PolyActiva’s privacy policy explains how personal information collected on its website is used and safeguarded.